India, June 4 -- This Small-cap Pharma Stock, engaged in the research and development of innovative pharmaceutical products, focusing on therapies for unmet medical needs, hit a 20 percent lower circuit after the company's key psoriasis drug, SCD-044, failed to get the expected result.

With a market capitalization of Rs. 5,172.87 crores, the shares of Sun Pharma Advanced Research Company Limited hit a 20 percent lower circuit of Rs. 156.50 per share on Wednesday, down from its previous closing price of Rs. 195.60 per share. Since then, the stock has retreated and is currently trading at Rs. 159.40 per equity share.

What is the news? Sun Pharma Advanced Research Company Limited (SPARC) has announced results from its drug SCD-044, also k...